Drug/Device Products High On Piper Analyst's List Of Y2K Trends
This article was originally published in The Gray Sheet
Executive Summary
The clinical efficacy of reducing restenosis by incorporating the anticancer agent paclitaxel with coronary stents is on the cusp of gaining greater clinical backing, Angiotech Pharmaceuticals indicated.